FDA Adverse Event Malfunction Summary report: N

NI

MDR report key: 6585945 · Received May 23, 2017

Report

Report Number
1416980-2017-04436
Event Type
Malfunction
Date Received
May 23, 2017
Report Date
July 19, 2017
Manufacturer
BAXTER HEALTHCARE CORPORATION
Product Code
FPA
PMA / PMN Number
NI
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
CA, US
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

THIS IS THE SECOND COMPLAINT EVALUATION FOLLOW UP. THIS FOLLOW UP IS TO ADDRESS THE PRODUCT CODE 2H5660. AS THE SAMPLE WAS NOT RETURNED AND THE LOT NUMBER IS UNKNOWN, A DEVICE ANALYSIS CANNOT BE COMPLETED. SHOULD ADDITIONAL RELEVANT INFORMATION BECOME AVAILABLE, A SUPPLEMENTAL REPORT WILL BE SUBMITTED.

Additional Manufacturer Narrative · 1

THE DEVICE WAS NOT RETURNED AND THE LOT NUMBER IS UNKNOWN; THEREFORE, A DEVICE ANALYSIS COULD NOT BE COMPLETED. SHOULD ADDITIONAL RELEVANT INFORMATION BECOME AVAILABLE, A SUPPLEMENTAL REPORT WILL BE SUBMITTED.

Additional Manufacturer Narrative · 1

THE BRAND NAME FOR 2N3350 IS MICRO-VOLUME EXTENSION SET; THE BRAND NAME FOR 2H5660 IS SOLUTION ADMINISTRATION SETS. CATALOG NUMBER - THE REPORTER INDICATED THAT THE INVOLVED PRODUCT CODE WAS EITHER 2N3350 OR 2H5660. MANUFACTURER - THE MANUFACTURING FACILITY FOR 2N3350 IS: (B)(4). THE MANUFACTURING FACILITY FOR 2H5660 IS: (B)(4). 510K NUMBER - THE 510K NUMBER FOR 2N3350 IS K113227; THE 510K NUMBER FOR 2H5660 IS K153158. (B)(6). SHOULD ADDITIONAL RELEVANT INFORMATION BECOME AVAILABLE, A SUPPLEMENTAL REPORT WILL BE SUBMITTED.

Description of Event or Problem · 1

IT WAS REPORTED THAT THERE WAS A LEAK FROM THE AIR VENT OF THE FILTER OF AN ADMINISTRATION SET. THIS WAS REPORTED TO HAVE OCCURRED EITHER DURING PRIMING OR DURING INFUSION. THERE WAS NO PATIENT INJURY OR MEDICAL INTERVENTION ASSOCIATED WITH THIS EVENT. NO ADDITIONAL INFORMATION IS AVAILABLE.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
366622 NI SET, ADMINISTRATION, INTRAVASCULAR FPA BAXTER HEALTHCARE CORPORATION NA ASKU

Patients

Seq Age Sex Outcome Treatment
1